# SPEAKERS AND CHAIRPERSONS

**Adrian van den Hoven - Director General, Medicines for Europe**

Adrian van den Hoven has been director general of Medicines for Europe since September 2013. In his role he focuses on stimulating competition in off-patent medicine markets, fostering access to medicine, reducing medicine shortages and addressing major health crises, supporting policy measures for sustainable pricing, promoting efficient regulatory standards, and developing a coherent EU industrial strategy to support the long-term viability of the generic, biosimilar and value-added medicines industries. He is also member, and former president, of the European Medicines Verification Organization (EMVO) board for the implementation of serialization against falsified medicines, the vice-chair of the International Generic and Biosimilar medicines Association (IGBA) and a member of the joint industry advisory council of the Health Emergency and Response Authority (HERA).

**Catherine Drew – Partner, Pinsent Masons**

CATHERINE DREW is a Partner at Pinsent Masons LLP in London. Catherine is a regulatory and patent specialist focusing on the life sciences sector with a degree in pathology. Catherine has advised for over 15 years on UK and pan-European patent litigation and administrative litigation concerning regulatory exclusivity rights, attaching to products in the life sciences sector. Catherine has assisted clients in litigation before the English High Court, Court of Appeal & Supreme Court, in addition to the European General Court. Notable cases include advising Accord Healthcare on proceedings seeking revocation of three patent families protecting a blockbuster oncology therapy; assisting Teva in bringing proceedings before the European General Court seeking clarification of the interpretation of the Orphan Regulation; assisting Sandoz in resisting judicial review proceedings brought in the English High Court seeking suspension of Sandoz's marketing authorisation for its transdermal patch product; and assisting Medicines for Europe on its interventions in Supreme Court proceedings in two landmark patent litigation matters. In addition, Catherine advises clients on the interpretation of UK and European medicines and medical device regulation, including providing strategic advice to clients seeking to bring products to market. Catherine has a good understanding of the commercial drivers to clients' business, having undertaken two secondments in a large multinational pharmaceutical company.

**Florian Schmidt - Deputy-Head Unit D1, DG Sante European Commission**

Florian Schmidt is the deputy head of unit of the Commission's pharmaceutical unit D.1 in the Directorate-General for Health and Food Safety (DG SANTE). He is a lawyer by training and joined the Commission in 2004. Amongst other things, he was involved in the implementation of the new pharmacovigilance legislation and followed the paediatric regulation, as well as general legal matters and court cases. He is now working on the Pharmaceutical Strategy for Europe and its implementation.

**Marcin Rodzinka-Verhelle - EU Policy Adviser, Comité Permanent des Médecins Européens Standing Committee of European Doctors (CPME)**

Marcin Rodzinka-Verhelle is an EU Policy Adviser at the Standing Committee of European Doctors (CPME) which represents national medical associations across Europe. He focuses on pharmaceutical policy, antimicrobial resistance and medical devices. Marcin has a Master's degree in Public Health (Health Economics and Governance of Health Systems) from the Jagiellonian University Medical College in Cracow (Poland). He was the Vice-Chair of Sustainable and Healthy Lifestyles Committee of the 5th European Health Parliament. Prior to joining CPME, Marcin worked on health policy and global equitable access to health technologies with European Public Health Alliance, Global Health Advocates and Mental Health Europe. He also worked with the National Institute of Public Health in Poland.

**Ancel.la Santos - Senior Health Policy Officer, BEUC**

Ancel·la Santos is Senior Health Policy Officer at the European Consumer Organisation (BEUC), which brings together 46 consumer organisations from 32 countries. She follows closely EU pharmaceutical policy and defends consumer interests in this area. Before joining BEUC in May 2019, Ancel·la served as Senior Policy Advisor for Health Action International. In total, she has nine years' experience representing the positions of non-profit umbrella organisations before the EU institutions, and at the European Medicines Agency's Patients' and Consumers' Working Party. From 2011-2013 Ancel·la worked at the Siemens AG Representation Office in Brussels, in the healthcare sector. She holds a Bachelor's degree in Political Sciences and Public Administration, a Master of Science in International and European Politics, and a Master in Journalism.

**Dimitri Eynikel - EU Policy and Advocacy Advisor, Médecins Sans Frontières**

DIMITRI EYNIKEL has been working for Médecins Sans Frontieres/ Doctors Without Borders (MSF) since 2010; the last 6 years of which for the Access Campaign as a policy officer and representative to the European Union. In this position, he analyses EU policy and advocates better global access to affordable and high-quality medicines to the European institutions, in particular for people in crisis areas and excluded populations. During the COVID-19 pandemic, he co-coordinated the Access Campaign's policy team on global access to COVID-19 vaccines, tests and medicines. In recent years he has been called up to various hearings in the European and national parliaments and has been regularly quoted in international press. With some colleagues he published a peer-reviewed article on the impact of specific intellectual property law rules on access to medicines in Europe. Previously, Dimitri worked as an international staff member for Médecins Sans Frontières (MSF) on public health projects in Haiti, Afghanistan; Libya, Iraq and South Sudan. From 2012 to 2015 he was based in South Africa. Dimitri Eynikel, graduated with a degree in history and an additional master's degree in international relations and conflict management.

**George Moore, Assistant General Counsel – Europe IP, Ex-NA IP Litigation, Viatris**

George Moore is Assistant General Counsel - Europe IP, Ex-NA IP Litigation, at Viatris. He currently leads the IP team at Viatris for Europe and the IP Litigation function for all ROW matters. He is a qualified solicitor (England & Wales) with a masters' degree in chemistry. He has over 15 years in-house pharmaceutical experience, having worked at Apotex in Canada and Sandoz in Germany. He previously worked in private practice in the UK, training and qualifying at Bristows, before then working at Allen & Overy.

**Sergio Napolitano - General Counsel and External Relations Director, Medicines for Europe**

Sergio Napolitano is General Counsel and External Relations Director at Medicines for Europe. At Medicines for Europe since January 2013, in 2018 he was nominated in a list of the 50 most influential people worldwide in IP law, policy and business. Before joining Medicines for Europe, Sergio Napolitano worked in the Directorate General for External Policies of the European Parliament and at the Permanent Representation of Italy to the EU on multilateral, plurilateral and bilateral trade negotiations, EU investment policy and IPR. Sergio Napolitano holds a degree in Law from the University of Naples Suor Orsola Benincasa and a LL.M. on EU and European Public Law from the University College of London (UCL).

**Paul Csiszár - Director, DG Competition, European Commission**

After graduating from ELTE School of Law of Budapest, Paul Csiszár studied international comparative law and earned a second Juris Doctorate at Loyola Law School in the United States. Following his admission to the California Bar in 1986 he practiced as a corporate, securities and M&A lawyer in the US and then from 1997 in Europe with the international law firm of Squire Sanders until 2003 when he joined the public sector. Currently Mr Csiszár serves as one of the Directors of the Directorate General for Competition of the European Commission.

**Stijn de Jong - Senior Associate, Stibbe**

Stijn specialises in European competition law and has extensive experience handling high-profile and cutting-edge antitrust investigations and litigations. His practice focuses on litigation matters, government investigations, antitrust regulatory approval, and general antitrust counseling. He advises a wide range of clients in diverse industries, including pharmaceuticals, consumer products, life sciences, transport, media, manufacturing and technology. Stijn has contributed articles to leading Dutch and European journals. In 2021, Stijn was seconded to Cravath, Swaine & Moore LLP in New York.

**Steve Rowan - Vice President, European Patent Office**

Stephen Rowan joined the EPO in January 2019 as Vice-President for DG1 – Patent Grant Process. He is responsible for the entire Patent Grant Process, from the receiving of applications up to and including opposition and the grant of the patent. This area also includes Quality and Business and User Services. Located in The Hague, Steve Rowan is Site Manager for the branch of the EPO, which is the largest international organisation in the Netherlands. Before joining the EPO, Stephen Rowan held a number of senior leadership roles in the Intellectual Property Office of the United Kingdom. These included the position of Director of Registered Rights, responsible for the end to end processing of patent, trade mark and design applications and the associated tribunal functions. Stephen Rowan joined the UK IPO in March 1991 and, in addition to his operational roles, sat as a Principal Hearing Officer and worked on a range of policy issues covering industrial property and copyright. He was Head of the UK Delegation to the Beijing and Marrakesh Diplomatic Conferences and was seconded to the Prime Minister's Strategy Unit (2004) and HM Treasury (2006) - working on the Gowers Review of IP. He has an LLB (Hons) from the University of the West of England.

**Ellen F. M. ‘t Hoen LLM PhD - Director Medicines Law & Policy**

Ellen ‘t Hoen (1960) is the director of Medicines Law & Policy, a group of legal and policy experts offering advice to international organizations, NGOs and governments. She is also a Global Health Law Fellow at the law faculty of the University of Groningen. She is the founder and former executive director of the Medicines Patent Pool. She has published widely and is the author of several books. In 2017 she received the Prix Prescrire for her book “Private Patents and Public Health: Changing intellectual property rules for public health.” In 2020, she was appointed Officer of the Order of Oranje-Nassau, a Dutch royal award given in recognition of her work on access to medicines. She has a master’s degree in law from the University of Amsterdam and a PhD from the University of Groningen.

**Karin Pramberger - Head of IP, Polpharma Group**

Karin joined the Polpharma Group as Head of IP in 2018. She is responsible for all global patent and trade mark related activities. Prior to joining the Polpharma Group, Karin worked in various positions in the patent departments of Pharmaceutical companies after having spent 7 years in a law firm in Vienna, Austria, where she became European and Austrian patent and trade mark attorney. She studied Biotechnology in Vienna, Austria, and at the Ecole Nationale Supérieure de Chemie de Paris, France. In 2017 she graduated with an LLB from the University of London. Since 2005 she is a tutor at CEIPI, University of Strasbourg, for the pre-exam and the C-part of the European Qualifying Exam, and since 2006 she is an active member of the Legal Affairs Committee of Medicines for Europe.

**Andreas Schillack, Head Legal Europe, Sandoz**

| | |
|---|---|
| 2018 – today | Head Legal Region Europe at Sandoz |
| 2017 – 2018 | Head Legal Region Western Europe at Sandoz |
| 2012 – 2017 | Country Head Legal & Compliance Germany at Novartis |
| 2007 – 2011 | Head of Legal Region Central Eastern Europe Middle East Africa at Merck & Co. |
| 1999 – 2007 | Head of Legal Germany at Eli Lilly & Company |
| 1996 – 1999 | Attorney at Law at Clifford Chance |
| 1995 – 1996 | Attorney at Law at Kasper, Knacke, Schäuble |

**Kristin Cooklin - Head of Intellectual Property, Zentiva Group**

Kristin Cooklin is the Global Head of Intellectual Property at Zentiva in Prague. Kristin and her team are responsible for supporting clients with respect to all IP Issues at all stages- including development, in-licensing, litigation and launch. In 2014 she joined Novartis where she held several different roles in its Sandoz Division in Munich, Germany, most recently as the Global Head of IP Litigation ex-US. In 2018 Kristin left Novartis to join the Zentiva and lead and transform the IP team after divestment from Sanofi. Prior to going in-house at Novartis Kristin spent over a decade in Washington DC working in AmLaw 100 law firms as a patent litigator, focusing primarily on pharmaceutical and life sciences litigation. Kristin is a US attorney at law and patent attorney. She has handled counseling, litigation and launches of pharmaceutical products across the world with a focus on the US and Europe and was responsible for the successful IP strategy and launch of several of the first biosimilar products launched around the world.

**Matthew Royle - Partner, Taylor Wessing**

Matthew specialises in patent litigation, opinion work, supplementary protection certificates (SPCs), paediatric extensions and regulatory advice. Matthew has a strong science background, holding a PhD in molecular immunology, meaning he gets to grips with the scientific facts of a case quickly. A leading individual in Chambers and is a rising star in litigation, Matthew has particular experience of acting for clients in the pharmaeutical, biotech and life sciences sectors. He regularly co-ordinates pan-European litigation and has been involved in hearings in Germany, Netherlands, Belgium and Norway.

**Ann Keelan - Director Compliance & Ethics UK, Teva**

Ann Keelan is Director of Compliance & Ethics at Teva Pharmaceuticals, supporting the UK & Ireland cluster and also Teva's respiratory business in Europe. She has 24 years' experience in pharma, a first class Law degree, and since joining Teva ten years ago she qualified as a solicitor. After starting in the industry as an IT project management contractor with GlaxoWellcome in 1999, she worked for numerous global pharmaceutical businesses, developing and implementing complex procedures, contributing to major business change projects, and over time developing a focus on quality- and compliance-related assignments in various business functions. As well as gaining extensive experience of project management, operational excellence, stakeholder engagement, and working with international teams and diverse cultures, Ann discovered a passion for developing and implementing corporate and local policies and SOPs. She was a significant contributor to the current Medicines for Europe Code of Conduct. Outside work, Ann is an active Soroptimist – currently working with a local university on a project to combat period poverty – and an occasional volunteer archaeologist.

**Natasha Liston Williams - Head of Compliance Europe, Global Compliance, Viatris**

Natasha Williams is the Head of Compliance - Europe for Viatris, formed in November 2020 through the merger of Upjohn (a former division of Pfizer) and Mylan. Since joining the company in September 2018, Natasha leads the design, operation, and continuous improvement of the compliance program for Viatris' Developed Markets Europe businesses. Before joining Viatris, Natasha served as SVP of Privacy and Data Protection Officer at Teleperformance, where she was responsible for the development, implementation, and administration of Teleperformance's data privacy program in the UK & CEMEA region. As a former Global Litigation and Investigations Director at Sanofi, Natasha oversaw the company's cross-border discovery activities, including designing the strategy for the processing and transfer of information for legal proceedings or investigations, in compliance with data protection laws and blocking statutes. Natasha is a member of the Medicines for Europe Code of Conduct working group and contributed to the revised version of the Code issued in February 2021.

**Kristof Roox - Partner, Crowell & Moring**

Kristof Roox is co-managing partner of Crowell & Moring's Brussels Office. He is a partner in the Intellectual Property Group and focuses on IP litigation, and in particular on complex patent litigation in the life sciences sector. With over 25 years of experience, Kristof has an impressive reputation before the Belgian civil and administrative courts, and also litigates before regulatory authorities and in the European courts. He will also deal with litigation before the new Unified Patent Court. He is widely respected for his pragmatic and creative approach to solving business disputes and for his to-the-point counselling. In addition to traditional IP litigation and counselling, Kristof is widely recognized for his thought leadership in relation to the regulatory aspects of life sciences. He advises companies and trade associations on launch and marketing strategies, data exclusivity and market protection, parallel imports, promotional practices, rebates, pricing and reimbursement, distribution models, OTC products, health care reforms, competition law aspects, etc. Furthermore, Kristof is an experienced litigator across a broad range of commercial and civil matters, covering all aspects of dispute resolution including ADR. With his deep knowledge of private international law issues, he often tackles complex multi-jurisdictional questions and he is reputed for his broad knowledge of procedural law issues.

**Christopher Dumont - Associate, Crowell & Moring**

Christopher Dumont is an associate in Crowell & Moring's Brussels office and is a member of the Intellectual Property Group. Christopher advises and assists clients in both contentious and non-contentious matters across the broad spectrum of IP/IT law. He also advises on commercial law and regulatory matters. Christopher has experience in advising and litigating complex trademark and patent litigation cases, including procedural aspects (e.g., use without due cause, Bolar exemption, Arrow declarations, priority rights, Gillette defense, locus standi). He has handled parallel import cases and European cross-border issues and advised on regulatory matters, IP portfolio management, and strategic planning.

**Imre Gonda - Director of Legal and IP department, Gedeon Richter**

Imre Gonda has been practicing national and international IP law for more than 20 years. Currently he is the director of Legal and IP Department one of the largest pharmaceutical companies in the Central European region which is very active in both areas, research of originating pharmaceuticals and generic product development. Previously he was head of Industrial Property Department. Before he joined Gedeon Richter Plc., he filled different positions in the Hungarian Intellectual Property Office, for 10 years he was the deputy-head of Trademark, Model and Design Department. He was responsible for managing and supervising the operation of national and international trademark, geographical indication and design sectors. He was involved in norm setting procedures including the preparation of amendments of laws and the creation of new international legal instruments. He participates in different international forums on a regular basis at WIPO and EU institutions, he was the elected vice-chair for eight cycles of the WIPO Standing Committee on the laws of Trademarks, Designs and Geographical Indications which forum was chaired by him for two years. He was participating in different forums of EUIPO (e.g. Management Board and Budget Committee; Liaison Meeting) in his national capacity for a considerable time period. He is qualified as a lawyer in Pázmány Péter Catholic University (Budapest) and did post graduate studies in European Law (LLM). He has written and edited several publications and books.

**Jurgen Figys - Counsel, Crowell & Moring**

Jurgen Jurgen Figys is a senior counsel in Crowell & Moring's Brussels office and a member of the Intellectual Property Group. Jurgen is one of the few lawyers in Belgium to be also trained as a biomedical scientist. He is therefore able to combine his scientific reasoning with his legal knowledge, a considerable asset in the technology-driven IP field. Jurgen predominantly works with clients in the pharmaceutical and biotechnology industries, with a particular focus on complex patent litigation and regulatory advice. He has particular experience in patent litigation with regard to invalidity, third-party opposition proceedings against counterfeit seizure, and preliminary injunction proceedings. His pre-contentious experience includes freedom-to-operate patent analyses and drafting protective letters. Jurgen is also involved in a number of trademark cases, such as parallel import litigation. Within life sciences, Jurgen provides strategic regulatory advice to pharmaceutical and biotech companies as well as national and European industry associations. His experience covers a broad range of regulatory issues like data exclusivity, EU marketing authorizations, pricing and reimbursement of medicinal products, advertising, medical devices, clinical trials, and data. Digital transformation in the health sector is also one of his main focus areas. Thanks to his scientific background, Jurgen is also able to advise clients on other EU regulatory issues with a technical angle. For example, Jurgen has an impressive, substantive knowledge of REACH through his work for a wide range of U.S. and EU-based clients. He also regularly advises on CLP issues. In addition, he assists clients with their more science-driven submissions to the European Chemicals.

**Agnieszka Deeg-Tyburska, Head of Legal, General Counsel, Member of the Management Board of ZF Polpharma**

Agnieszka Deeg-Tyburska has been working as the Chief Legal Advisor of the Polpharma Group since 2015. Currently, he manages the legal, organizational, compliance, security and patents teams. She is also the Vice-President of the Legal Committee of Medicines for Europe. Since 2022 she holds the title of Certified CERP Mediator. Agnieszka has been associated with the pharmaceutical industry for many years, representing generic and innovative producers in regulatory and patent related matters as well as in large and sophisticated transactions. She has extensive experience in M&A transactions with particular emphasis on acquisitions of public companies, investment transactions of venture capital funds. Email: agnieszka.deeg-tyburska@polpharma.com

**Maciej Jamka – Senior Partner, DWF Poland Jamka sp.k.**

Meet Maciej Jamka, an accomplished advocate who practices in all areas of Polish and international law, specializing in international arbitration and litigation. He heads the litigation and arbitration practice of DWF Poland and has successfully represented clients in some of Poland's most significant litigation cases. He has also counselled major international companies and the Republic of Poland in investment arbitration proceedings. Maciej has extensive experience in arbitration proceedings based on the rules of major international institutes such as the ICC, SCC, VIAC, and UNCITRAL. He has also been appointed as an arbitrator in international commercial disputes. In recognition of his expertise, Maciej has served as the President of the Polish National Committee of ICC from 2012 to 2018 and is currently a Member of the ICC Court of International Arbitration. He is highly recommended by Chambers & Partners and Legal500, with consistent recognition in Band 1 and the coveted title of "Most in demand arbitrators."

**Corinna Sundermann - Senior Vice President Intellectual Property, Fresenius Kabi**

Corinna Sundermann is heading the IP department of the Pharma Division at Fresenius Kabi. She joined Fresenius Kabi in 2008 as a Manager and built the IP department from 1 to 40 FTE since then. She is Senior Vice President since 2012 and took over responsibility for copyright within Fresenius as well. Focus concerning patents is on generics, branded products, clinical nutrition and medical devices. Characteristic for the department is, to a certain extent, internal handling of litigation. Before joining Fresenius Kabi, she worked 10 years for an originator company, 5 years as a Head of Combinatorial Chemistry, 5 years in the IP department and is European Patent Attorney since 2006. She holds a Dr. rer. nat. from the University of Jena and a diploma in chemistry from the University of Frankfurt.

**Rachel Goode - Senior Vice President, Head of Legal & IP, Biopharmaceuticals, Fresenius Kabi**

Rachel Goode is Senior Vice President, Patents and Legal at Fresenius Kabi. She leads a team of in-house attorneys and is responsible for the global patent and legal strategy of the biosimilars business. Prior to working for Fresenius Kabi, Rachel worked at the Teva where she acted as in-house counsel for the biosimilars business. Before joining Teva, Rachel worked as a patent attorney for the EMD Serono biosimilars unit where she was the Patents Lead for several biosimilar products. Rachel began her career in intellectual property as a patent attorney in a law firm in the UK. She is licensed as a Patent Attorney under European patent law and is a member of the UK chartered Institute of Patent Attorneys (CIPA). Rachel graduated from the university of Sheffield, UK with a 1st class honors degree in Biochemistry and a PhD in Molecular Biology.

**Patricia Cappuyns - Partner, Taylor Wessing**

Patricia Cappuyns is a Partner in the Intellectual Property practice group. She specialises in patent litigation, mostly in the life sciences sector and in FRAND cases. Patricia has been active in a wide range of sectors, including pharma, biotech, technology, construction, the chemical industry, telecommunications and mechanical engineering. For 7 years, she taught Patent Law as an Associate Professor at the University of Liège in their LL.M. program in IP and Competition Law, and she is currently teaching the Intellectual Property Law course at the Brussels School of Governance. She regularly publishes articles about patent-related topics, most recently in the Journal of Intellectual Property Law and Policy, and often speaks at conferences.

**Petra Bohanec Grabar - Group Head, IP, IP Small Molecules, Sandoz International GmbH**

Petra Bohanec Grabar is a Slovenian and European Patent Attorney with extensive experience working in house. Petra embarked on her journey with the Sandoz group in 2010, where she began her career as a patent attorney trainee at Lek d.d in Ljubljana, Slovenia. In 2012, she relocated to Munich to join Hexal at its headquarters in Holzkirchen. Since 2017, Petra has been entrusted with the leadership of patent practitioner teams, initially as the Therapeutic Area Lead and later assuming the role of Group Head in 2022. Furthermore, Petra holds a PhD in Biochemistry and Molecular Biology from the Faculty of Medicine, University of Ljubljana. Additionally, she has attained the diploma of Patent Litigation in Europe from the University of Strasbourg, further enhancing her expertise in this field.

**Joshua Cravigan – Senior Patent Counsel Generics – Europe, Viatris.**

Joshua currently leads the generics IP team at Viatris for Europe. He is a qualified European Patent Attorney with a degree in Analytical Chemistry. Joshua has over 20 years' experience in the generic pharmaceutical industry. He began his career as a research chemist in his native Australia for Alphapharm (Merck Generics group) in 2001. After transferring to the UK in 2007 with Merck Generics, Joshua's work involved carrying out testing to support European patent litigation and EPO oppositions, which facilitated a move to the Legal team in 2008. Since then Joshua has focused on an extensive portfolio of EPO oppositions for Viatris and support of national litigation.

**Saufung Ma - Accord Healthcare**

Saufung looks after Accord Healthcare's IP and regulatory EMENA strategies. His roles include managing litigations, patent prosecution, brand protection and IP licensing.

**Charlotte Weekes - Strategic Patent Litigation Partner (Life Sciences specialist), Pinsent Masons**

Charlotte Weekes is a UK and Irish qualified solicitor with over 15 years' experience handling pan-EU, business critical patent and SPC actions in the life sciences sector, primarily in the pharmaceutical field. She regularly acts on patent and SPC litigation before the UK High Court and Court of Appeal and has represented clients in precedent setting cases before the Supreme Court of England and Wales and the CJEU (including Teva v Gilead), as well as in the first SPC case to go to trial in the UK since Brexit. Charlotte's understanding of her clients' commercial goals is always reflected in her approach to litigation, and strategic advisory work in the context of getting on the market and maintaining market position in line with commercial aims. Charlotte is ranked in the Top 250 Women in IP by IP Stars and two of her cases have won Managing IP Case of the Year awards in recent years. She "provides thoughtful, directed advice for clients and has a real understanding of the industry and what matters in litigation and the best strategies to employ" (Legal 500 2022). Ranked Leading Individual in Patents and Next Generation Partner in Life Sciences & Healthcare in Legal 500, Charlotte was also shortlisted for the "Practitioner of the Year Award" at the Managing IP Awards 2020.

**Judith Krens - Head of Life Sciences (partner), Pinsent Masons**

Judith Krens leads the Life Sciences practice of Pinsent Masons in the Netherlands. Judith has a degree in law and in chemistry. Patent law has been her passion since the start of her career. She has two decades of experience with cross-border patent and SPC litigation in the field of pharmaceuticals, biotech and medical devices.

Clients describe her as a highly skilled and stand-out partner for such matters in the region. As a life sciences specialist Judith assists clients with complicated matters in pharmaceutical and medical device regulatory law. She has deep knowledge of the sector. Judith further has worked in the M&A and private equity team of Debevoise & Plimpton in New York, which gave her top-class experience in negotiating IP licenses and transfer agreements. She is Dutch (Amsterdam bar) and US (NY bar) qualified. Judith is one of the co-founders of the Female IP Experts (FIPE) network in the Netherlands. She frequently speaks at international and national conferences on pharmaceutical and biotech patent litigation.

**Alpha Indraccolo - VP and General Counsel, European IP and Regulatory Litigation, TEVA**

Alpha Indraccolo joined the European IP and Regulatory Litigation team at Teva in 2013. She has led the team since 2018 covering matters relating to IP and regulatory litigation as well as support to IP aspects of government affairs in the European region. Alpha is a qualified solicitor (England & Wales) with a MSc in Molecular Biology from New York University and a BA from Barnard College. Before joining Teva, Alpha worked in private practice at Bird & Bird, London specialising in patent litigation.

**Professor Anthony Serracino Inglott - Chair of the Medicines Authority of Malta**

Anthony Serracino-Inglott is a Professor at the Department of Pharmacy, Faculty of Medicine and Surgery of the University of Malta and Chief Executive Officer of the Malta Medicines Authority. Professor Serracino-Inglott studied pharmacy at the University of Malta and is a registered pharmacist. He continued his postgraduate studies at the University of Cincinnati, USA where he obtained a Doctorate degree and completed a residency at the University of Cincinnati Medical Centre. His research interests are in the fields of biopharmaceutics and pharmacokinetics, pharmaceutical regulatory sciences, patient safety, personalised medicine and pharmacy education. Serracino-Inglott's experience includes being a court expert in toxicology and forensic sciences, advisory role to government entities and a Qualified Person for the pharmaceutical industry. He has contributed to the evolvement of health-systems through his high profile interventions at regional and global meetings. He was instrumental in developing patient-centred pharmaceutical services and in establishing models in pharmacy education that contribute to innovation in pharmacy. Professor Serracino-Inglott is active in pharmaceutical regulatory sciences promoting international collaboration in propagating safety, efficacy, quality of medicines and patient access to medicines. He is a member of the Management Board of the European Medicines Agency.

**Nora Wessendorf - Attorney at Law, Taylor Wessing**

Dr. Nora Wessendorf is a patent litigator who represents clients in patent, SPC and utility model infringement proceedings before the German courts. She is a salary partner in Taylor Wessing's Dusseldorf office. As a member of Taylor Wessing's Patents Technology & Life Sciences team, she advises clients in the fields of, among others, medical technology and digital health applications as well as pharmaceuticals, biotech, chemistry and personalized medicine.
She also advises clients on product launches and transactional matters, in particular licensing agreements, R&D agreements and in the context of corporate transactions. Nora received a doctorate from the University of Muenster, Germany, after completing a thesis analyzing the impact of the America Invents Act on patent law harmonization in Germany and the US. She further received an LL.M. in intellectual property law from the George Washington University Law School in Washington, D.C. She is admitted to practice law in Germany and in the State of New York. She co-authored the chapters on SPCs, patent infringement and evidence in Germany in the 2nd edition of "A Practitioner's Guide to European Patent Law: For National Practice and the Unified Patent Court" (Hart Publishing, 2022), and regularly publishes and speaks on issues of pharmaceutical patent law. Nora is also an active member of the International Association for the Protection of Intellectual Property (AIPPI).

**Denis Dambois - Legal and Policy Officer, Directorate General for Internal Market, Industry, Entrepreneurship and SMEs (DG Grow), European Commission**

After graduating in electromechanical engineering from the Brussels University (ULB) in 1987, Denis was hired as a researcher in power electronics by Philips. In 1991 he joined the patent department of Solvay, a multinational chemical company. During that period he trained in intellectual property at the CEIPI (Strasbourg) and qualified as a European Patent Attorney. In 1999 Denis was hired by the European Commission. For several years he was with the Directorate-General for Research, dealing with R&D-related IP and technology transfer issues, before moving to the IP unit of DG Trade, responsible for international IP issues. From 2013 to 2016 he was heading the Research and Innovation Section of the Delegation of the European Union to India (Delhi), where he fostered EU-India research collaborations, and also handled IP issues. Since 2017 Denis is part of the IP unit of DG GROW, which is the main unit of the Commission responsible for IP policy, where he is mainly working on patent-related policy.

**Dr Roberto Romandini, LLM Munich; independent; former Affiliated Research Fellow (2020-2022) and Senior Research Fellow (2012-2019) of the Max Planck Institute for Innovation and Competition**

Dr Roberto Romandini holds a law degree from the University of Pisa and an LL.M. degree from the University of Munich, where he specialised in patent law. He completed his Ph.D. thesis on the patentability of human stem cells at the LMU in Munich, before practising intellectual property law for 5 years at a leading IP firm in Milan. From 2012 to 2019, he worked as a Senior Research Fellow at the Max Planck Institute for Innovation and Competition in Munich. In this position, he led and co-authored the first MPI study on SPCs, published in 2018.

In 2020-2022, on behalf of the Max Planck Institute, he wrote the "Study on the Options for a Unified Supplementary Protection Certificate (SPC) System in Europe" for the European Commission. The views expressed in this study (and in today's presentation) are the author's own and do not reflect the views and opinions of the European Commission or the EPO Boards of Appeal, for which Dr Romandini has been working since 2019.

**Sven J.R. Bostyn - Associate Professor of Innovation Law, University of Copenhagen**

Dr. Sven J.R. Bostyn (LLB, Lic. Jur., LLM law, PhD law) is Associate Professor of Biomedical Innovation Law at the Centre for Advanced Studies in Biomedical Innovation Law (CeBIL http://cebil.dk), Faculty of Law, University of Copenhagen. He also lectures at the Institute for Information Law (IVIR) of the University of Amsterdam. He is also a regular guest professor at CEIPI in Strasbourg. He is specialized in all areas of IP law, with special emphasis on patent law relating to pharmaceuticals, biotechnology, medical devices, software, Artificial Intelligence and SPC's. Sven is one of the most prominent authorities in Europe in the area of patent law. He is also specialised in regulatory exclusivities (data and market exclusivity, orphan drug designation etc.), and researches more generally also innovation incentivising mechanisms. He has written extensively on most areas of patent law, and apart from those subjects already mentioned, he has also published in the field of plant patent protection, plant variety rights, software related inventions, European and international harmonization of patent law and the Unitary Patent system. Sven has also been in private practice for the last 14 years where he advised and advises clients on most aspects of patent law, competition law, licensing and regulatory exclusivities. He also acted and acts as an expert witness in court cases. He was from 2013-2016 the Chair of the Expert Committee at the European Commission on the development and implications of patent law in the field of biotechnology and genetic engineering. Sven is the single author of more than 60 scientific publications in the aforementioned areas, and is a regular speaker on international conferences, where he speaks on a wide variety of topics, including IP protection in life sciences, pharma patents, SPC's, regulatory exclusivities in life science, IP issues relating to software and artificial intelligence, patent protection for plants and plant variety rights systems.

**Martijn de Lange - Patent Examiner, Netherlands Patent Office**

Dr. Martijn de Lange was trained as a chemist. Since 2001 he works for the Netherlands Patent Office. He divides his time between examining patent applications and applications for supplementary protection certificates (SPCs) for pharmaceuticals, and the paediatric extensions thereof. He also represents the Netherlands Patent Office at the Dutch courts when appeals against decisions on SPCs are filed and has been involved in the drafting of the observations of the Netherlands government in the last 7 referrals before the Court of Justice of the European Union. In March 2021 and January 2023 he organized SPC Expert Meetings where examiners from the national patent offices in Europe informally discussed the latest case law and developments.

**Elizabeth Wright - Associate General Counsel, European IP and Regulatory Litigation, Teva**

Elizabeth Wright joined the European Regulatory and IP Litigation team at Teva Pharmaceuticals in 2020. She takes the lead for all regulatory litigation and legal support in Europe, as well as covering government affairs and IP litigation matters. Elizabeth is a qualified solicitor advocate (England & Wales) with a PhD in Genetics from Cambridge University. Before joining Teva, she spent 10 years working in private practice at Bird & Bird.

**Marleen van den Horst - Attorney at all/Partner, La Gro Geelkerken Advocaten**

Dr. Marleen van den Horst is a partner in the IP & Technology department of LGGA (La Gro Geelkerken Advocaten). She is a member of the firm's Healthcare & Life Sciences Industry group.

**Practice outline:** Marleen has over 28 years of experience in litigating and coordinating multi-jurisdictional patent cases. She is internationally renowned for having successfully represented clients in many patent disputes in all fields of technology: mechanical engineering, life sciences, chemistry and high tech/telecoms.

She is worldwide regarded an authority for her in depth industry knowledge and experience in the life sciences, including litigation and advice not only on patents, SPCs and PEs regarding pharmaceutical products and medical devices, but also on regulatory issues and product liability.

**Farma & Life Sciences:** Marleen has acted as lead counsel in multiple (cross border) patent/SPC proceedings and has advised and represented clients like Viatris (Mylan), Accord Healthcare, Stada, Bayer, Aurobindo, Insud Pharma (Chemo), Sandoz, Teva, Tiefenbacher, Alvogen/Adalvo and Amgen in respect of great many blockbuster drugs, both small molecules (generics) and complex molecules (biosimilars).

**Pro bono work:** For more than a decade Marleen pro bono advises the NeoKidney Foundation on all the patent related issues and other legal aspects of the development of an artificial portable kidney.

**Recognition:** She is recognized as a leader in the field in Chambers Global & Europe, Legal 500 and IAM Patent 1000. 'Marleen van den Horst is incredibly well connected and respected, a skillful strategist and a great person to work with' (Legal 500). "With enthusiasm and skill, Marleen van den Horst clearly shows why she rightly belongs at the top in the Netherlands." Legal 500, 2022

**Publications & International Presentations**

* Marleen holds a doctorate from VU University Amsterdam and has published a number of books and articles while working at the university prior to going into private practice.

* Together with UK solicitor Duncan Curley, Marleen is the author of the second edition of the acclaimed chapter 6 in the book entitled "Overlapping IP Rights", published by Oxford University Press. Chapter 6 deals with Patents and Regulatory Data Exclusivity for Medicinal Products.

* Marleen is frequently asked as a speaker/moderator at international conferences on patent/SPC topics, e.g. by:

o Waseda University (Tokyo): Conference on UPC (4 March 2023)

o LESI: Global webinars on UPC (9 November 2022, 15 February, 15 March and 18 April 2023,

o Fordham University New York: Speaker at the Annual IP Conference (13 April 2023)

**Victor van de Wiele - University of Cambridge**

Victor is an affiliated researcher at PORTAL and a current PhD Candidate in Law at the University of Cambridge. Victors holds a bachelor's degree in law (LL.B.) from Queen Mary, University of London (UK) and a Masters in Laws (LL.M.) in Global Health Law with a Food & Drug Law Certificate from Georgetown University Law Center. Victor's research predominantly examines how patents and patent litigation pathways may form barriers to market access for generic and biosimilar drugs. Other areas of interest include: pharmaceutical competition, drug pricing and regulatory exclusivities. Victor has published in journals like Nature Biotechnology, Health Affairs, JAMA Internal Medicine and the Lancet Diabetes & Endocrinology. You can follow Victor on Twitter (vdw_victor).

**Alexander Ott - Senior Patent Attorney, Sandoz**

Alex is a German and European Patent Attorney and Senior IP Counsel at Hexal AG/Sandoz, located in Holzkirchen, Germany. He joined Sandoz in 2008 after 3.5 years in private practice at Wuesthoff & Wuesthoff, Munich. In his current role, he is focusing primarily on guiding the global development, supporting multi-jurisdictional IP litigation, and enabling launches worldwide of Sandoz's biosimilars. Since 2019, Alex is also representing Sandoz at the Legal Affairs Committee of MfE.

**Ana Marti - General Counsel & IP, Medichem**

Ana Martí is General Counsel at Medichem, S.A., a Spanish headquartered company devoted to the development and manufacture of active pharmaceutical ingredients and generic medicines. Her role includes, in addition to legal, IP and regulatory affairs of the group of companies. She has more than 20 years' experience in the pharmaceutical industry, mainly acquired in the generic sector. She is qualified as a Spanish attorney at law and completed executive education at ESADE Business School. Before joining Medichem, she worked several years at a Spanish law firm advising life science clients on commercial transactions and regulatory and IP matters. Ana has also participated as co-author of a book on pharmaceutical marketing and is currently member of the Board of Medicines for Europe.

**Julia Pike – Global Head of IP, Sandoz**

Since March 2020, Julia has been the Global Head of IP for Sandoz, a leading generic and biosimilar company in the process of being spun-off from Novartis. After leaving private practice in Australia in 2002, Julia has been in-house counsel for generic pharmaceuticals including at Mayne Pharma and Hospira Inc, before joining Sandoz in 2008. In her previous roles with Sandoz, she led the global IP litigation function and was proud to be part of the first wave of US biosimilars litigation, culminating in the landmark US Supreme Court decision, Sandoz v Amgen. She has maintained a keen interest in IP strategy and litigation worldwide, including cases arising under the Hatch-Waxman and BPCIA legislation in the US, PM(NOC) regulations in Canada and litigation arising from patent linkage systems around the world. She is particularly excited about the opportunity to shape the new Sandoz IP strategy, including taking a more active role in shaping global IP policy, having started at Sandoz in European public affairs.